Dermata Therapeutics Inc
NASDAQ:DRMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (18.2), the stock would be worth $-53.07 (4 312% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.4 | $1.26 |
0%
|
| Industry Average | 18.2 | $-53.07 |
-4 312%
|
| Country Average | 21.9 | $-63.75 |
-5 160%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Dermata Therapeutics Inc
NASDAQ:DRMA
|
5.1m USD | -0.4 | -0.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 65.8 | 43.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 21.2 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 51.5 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 12.1 | 15 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 9.4 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 23.6 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.3B USD | 24.6 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 19.9 | 17.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 21.9 |
| 70th Percentile | 36.5 |
| Max | 3 188 432.5 |
Other Multiples
Dermata Therapeutics Inc
Glance View
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2021-08-13. The firm focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate, DMT310, is a product candidate, which is developed from its Spongilla technology platform. DMT310 is a topical product derived from sourced freshwater sponge with multiple components. Its DMT310 is under clinical development for the treatment of acne vulgaris (acne), psoriasis vulgaris (psoriasis), and papulopustular rosacea (rosacea). The Company’s Spongilla technology platform is based on the use of a naturally growing freshwater sponge, Spongilla lacustris (Spongilla). Spongilla is a freshwater sponge that grows in rivers and lakes in commercial quantities in select regions of the world, such as the northern hemisphere. Its clinical development pipeline consists of DMT310 and DMT410.
